Neuroendocrine cancer ranges from highly curable to extremely aggressive, and “how bad” it is depends almost entirely on two factors: the tumor’s grade and how far it has spread. A slow-growing, localized neuroendocrine tumor caught early carries a 5-year survival rate as high as 97%. A high-grade neuroendocrine carcinoma that has reached distant organs can have a median survival measured in months. That enormous gap is what makes this cancer so difficult to generalize about.
Why the Grade Matters More Than the Name
Neuroendocrine neoplasms arise from cells scattered throughout the body that share features of both nerve cells and hormone-producing cells. They can appear in the lungs, pancreas, small intestine, colon, rectum, stomach, and other organs. But the single most important detail in any diagnosis is the grade, which describes how quickly the cancer cells are dividing.
Grade 1 and grade 2 tumors (often called NETs) grow slowly, sometimes over many years. Grade 3 neuroendocrine carcinomas (NECs) are fast-dividing, biologically aggressive cancers that behave more like small cell lung cancer than like their lower-grade cousins. A grade 1 tumor in the small intestine and a grade 3 carcinoma in the colon are both technically “neuroendocrine cancer,” but they are practically different diseases with very different outlooks.
Survival Rates for Slow-Growing NETs
Low- and intermediate-grade neuroendocrine tumors of the gastrointestinal tract have some of the most favorable survival statistics among all cancers. Data from the American Cancer Society, based on patients diagnosed between 2015 and 2021, show a 5-year relative survival rate of 97% for localized disease and 96% for regional disease (cancer that has reached nearby lymph nodes). Even when these tumors have spread to distant sites, the 5-year survival rate is 68%, and the overall rate across all stages is 94%.
Pancreatic neuroendocrine tumors tend to be somewhat more variable. Among patients who undergo surgery, 5-year survival reaches 93% to 100% depending on whether the tumor produces excess hormones. For those managed with medication alone, the numbers drop: roughly 70% for non-functional tumors and around 33% for functional ones that are actively secreting hormones and causing symptoms. Still, many people with pancreatic NETs live for years or even decades with the disease, particularly when it remains low-grade.
High-Grade Neuroendocrine Carcinomas
The picture changes dramatically with high-grade disease. Small cell and large cell neuroendocrine carcinomas are rare, fast-moving cancers that often present at an advanced stage. Colorectal data illustrate the severity. For stage IV small cell neuroendocrine carcinoma of the colon, median overall survival is just 2 months. Large cell carcinoma of the colon fares only slightly better at 5 months. Rectal primaries show similar patterns: 7 months for small cell and 6 months for large cell at stage IV.
When these high-grade cancers are caught at stage I, median survival extends to roughly 23 to 32 months for small cell types and over 100 months for large cell types, reinforcing how much stage matters even within aggressive disease. But because high-grade carcinomas grow quickly and often spread before symptoms appear, early detection is uncommon.
The Diagnostic Delay Problem
One factor that makes neuroendocrine cancer worse than it needs to be is how long it takes to diagnose. Many published studies based on patient surveys report delays of four years or more before a correct diagnosis. Among patients whose path to diagnosis ran through primary care, 25% needed three or more visits before being referred to a specialist.
The delay happens because neuroendocrine tumors produce vague symptoms: flushing, diarrhea, abdominal pain, wheezing. These overlap with irritable bowel syndrome, food intolerances, anxiety, and dozens of other common conditions. Slow-growing tumors can simmer for years without causing obvious alarm, which is both a blessing (the cancer isn’t racing ahead) and a curse (it has time to spread before anyone looks for it).
Carcinoid Syndrome and Heart Damage
Some neuroendocrine tumors, particularly those originating in the small intestine, release excess serotonin and other substances into the bloodstream. This causes a cluster of symptoms known as carcinoid syndrome: episodes of facial flushing, persistent diarrhea, wheezing, and sometimes rapid heart rate. It typically occurs after the cancer has spread to the liver, which can no longer filter out the excess hormones before they reach the rest of the body.
The most serious complication is carcinoid heart disease, which develops in an estimated 25% to 65% of patients with carcinoid syndrome. The excess serotonin damages heart valves over time, causing them to stiffen and leak. Left untreated, this leads to heart failure. Patients with untreated carcinoid heart disease have a 3-year survival rate as low as 31%, compared to 68% for carcinoid syndrome patients whose hearts remain unaffected. Mortality rates are roughly double: 27.8% versus 13.0% over the same period. Valve replacement surgery can be life-saving when the damage is caught in time, which is why regular heart monitoring with echocardiograms is a standard part of care for anyone with carcinoid syndrome.
How Treatment Has Changed
Treatment for neuroendocrine cancer has evolved significantly in recent years, and this directly affects how “bad” a diagnosis is today compared to a decade ago. For slow-growing tumors, long-acting hormone-blocking injections remain a cornerstone. They control symptoms and can slow tumor growth for years. A newer option, a targeted radioactive therapy that homes in on receptors found on most neuroendocrine tumor cells, has shown strong results. In a recent clinical trial, this therapy combined with standard hormone-blocking treatment delayed disease progression to a median of 22.8 months, compared to 8.5 months with hormone-blocking treatment alone, in patients with higher-risk grade 2 and grade 3 tumors.
For pancreatic neuroendocrine tumors specifically, a chemotherapy combination using temozolomide has become routine in the United States, replacing an older, less convenient regimen. And for patients with advanced, high-grade tumors that cannot be surgically removed, doctors now sometimes use a course of chemotherapy first to see how the cancer responds before deciding on the next step. This “test the biology” approach helps tailor treatment to each patient’s tumor behavior rather than relying on a one-size-fits-all plan.
What Determines Your Individual Outlook
If you or someone you know has been diagnosed, the severity depends on a specific combination of factors, not a single label. The key variables are:
- Grade: Grade 1 tumors divide slowly and carry the best prognosis. Grade 3 carcinomas are the most aggressive.
- Stage at diagnosis: Localized disease is often curable with surgery alone. Distant spread narrows the options but does not always mean a short timeline, especially for low-grade tumors.
- Primary site: Small intestine and rectal NETs tend to have better outcomes than pancreatic or colonic ones at equivalent stages.
- Functional status: Tumors that secrete hormones create additional complications, including the risk of heart damage, that can independently affect survival.
- Ki-67 index: This is a lab measurement of how actively tumor cells are dividing. It directly determines the grade and helps guide treatment decisions.
The range of outcomes in neuroendocrine cancer is wider than in almost any other cancer type. A person with a small, localized, grade 1 rectal NET removed during a routine colonoscopy may never think about it again. A person with a grade 3 small cell carcinoma of the colon diagnosed at stage IV faces one of the most challenging scenarios in oncology. Both fall under the same umbrella term, which is why the answer to “how bad is it” always starts with: what kind, what grade, and how far.